- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04920292
PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets (HELP-OFZ)
December 19, 2022 updated by: Swiss Tropical & Public Health Institute
A Phase 1, Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of an Oxfendazole Tablet Formulation in a Randomized, Double-Blind, Placebo-Controlled Design After Single and Multiple Oral Dosing in Healthy Adult Volunteers
The study evaluates the pharmacokinetics (PK), safety and tolerability of oxfendazole, after administration as a tablet formulation in healthy male and female participants.
Study Overview
Detailed Description
This is a randomized, placebo-controlled, double blinded, single center phase I bioavailability study with two Single Dose cohorts and one Multiple Doses cohort in a total of 30 healthy male and female healthy volunteers (10 per cohort).
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bagamoyo, Tanzania
- Ifakara Health Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adult male and non-pregnant (confirmed by pregnancy test) and non-breastfeeding female participants (18 to 45 years of age at the time of consent).
- Willingness to give written consent to participate in the trial, after reading the participant information and consent form and after having had the opportunity to discuss the trial with the Investigator or any delegate.
- Ability to read and write and to understand the participant information sheet and the nature of the trial and any hazards from participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire trial.
- Women of childbearing potential (WOCBP) must agree to use a highly effective form of contraception in combination with a barrier method from at least 28 days prior to first dosage to 30 days after last dosage.
- Male participants must be willing to ensure the use of condoms from the first dosage to 90 days after last dosage.
- Normal body weight range (body mass index (BMI) between 18 and 29.9 kg/ m2)
Exclusion Criteria:
- Participation in another clinical trial within 3 months prior to the study, or within 5-times the half-life of the drug tested in the previous clinical trial, whichever is longer. (Time calculated relative to the last dose in the previous clinical trial).
- Regular daily consumption of more than one liter of xanthine-containing beverages (e.g. chocolates, tea, coffee or cola drinks).
- Regular daily consumption of more than 5 cigarettes daily.
- Use of a prescription medicine during the 28 days before the first dose of trial medication or use of an over-the-counter medicine, during the 7 days before the first dose of trial medication.
- Use of dietary supplements or herbal remedies (such as St John's Wort) known to interfere with the CYP3A4 and/or P-gp metabolic pathway during the 28 days before the first dose of trial medication.
- Therapies which may impact on the interpretation of study results in the opinion of the Investigator.
- Medical, social condition, psychiatric disorder or occupational reasons that, in the judgment of the Investigator, is a contraindication to protocol participation, may impair the volunteer's ability to give informed consent or effectively participate in the study, may significantly increase the risk to the volunteer because of participation in the study or may impair interpretation of the study data.
- Blood pressure and heart rate in supine position at the screening examination outside one (or more) of the ranges 105-136 mm Hg systolic, 58-84 mm Hg diastolic; heart rate 56- 96 beats/min.
- Febrile illness within 1 week before the start of study treatment.
- History of relevant diseases of vital organs, of the central nervous system or other organs.
- Participants with a history of allergies, non-allergic drug reactions, adverse reaction to any drug, or multiple drug allergies.
- Participants with a hypersensitivity to the investigational drug, related benzimidazole compounds or the control agent and/ or to inactive constituents.
- Presence or history of drug or alcohol abuse in the last 10 years.
- Surgery (e.g. stomach bypass) or medical condition that might affect absorption of study drug taken orally.
- Clinically relevant abnormal medical history, concurrent medical condition, acute or chronic illness or history of chronic illness sufficient to invalidate the subject's participation in the trial or make it unnecessarily hazardous.
- Relevant pathological abnormalities in the ECG such as a second or third-degree atrioventricular (AV) block, prolongation of the QRS complex over 120 msec or of the QTcF-interval over 450 msec (corrected interval according to Fridericia's formula).
- Positive test for hepatitis B or C.
- Positive test for HIV.
- Positive pregnancy test (WOCBP).
- Positive stool or urine test for helminth infestation by Kato-Katz, urine filtration or Baermann test.
- Positive for malaria by thick blood smear.
- Positive test for (neuro-) cysticercosis.
- Positive test for echinococcosis.
- Positive test for onchocerciasis.
- Presence of abnormal physical findings, ECG, or laboratory values at the screening assessment that could interfere with the objectives of the trial or the safety of the subject.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Dose of 100mg Oxfendazole versus Placebo
8 participants will receive a single oral dose of 100mg of oxfendazole.
2 participants will receive a single oral dose of placebo.
|
Oxfendazole is a benzimidazole anthelminthic drug.
The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
|
Experimental: Single Dose of 400mg Oxfendazole versus Placebo
8 participants will receive a single oral dose of 400mg of oxfendazole.
2 participants will receive a single oral dose of placebo.
|
Oxfendazole is a benzimidazole anthelminthic drug.
The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
|
Experimental: Multiple Doses of 400mg Oxfendazole versus Placebo
8 participants will receive multiple oral doses of 400mg of oxfendazole on 5 consecutive days. 2 participants will receive multiple oral doses of placebo on 5 consecutive days. |
Oxfendazole is a benzimidazole anthelminthic drug.
The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration curve from time zero to the last quantifiable concentration at time t (AUC0-t) of oxfendazole and its metabolites fenbendazole and fenbendazole sulfone
Time Frame: At different time points from pre-dose up to 48 hours after single dose administration
|
For single dose arms
|
At different time points from pre-dose up to 48 hours after single dose administration
|
Area under the plasma concentration curve (AUC) from time zero extrapolated to infinity (AUC0-∞) of oxfendazole and its metabolites fenbendazole and fenbendazole sulfone
Time Frame: At different time points from pre-dose up to 48 hours after single dose administration
|
For single dose arms
|
At different time points from pre-dose up to 48 hours after single dose administration
|
Maximum observed concentration (Cmax) of oxfendazole and its metabolites fenbendazole and fenbendazole sulfone
Time Frame: At different time points from pre-dose up to 48 hours after single dose administration
|
For single dose arms
|
At different time points from pre-dose up to 48 hours after single dose administration
|
Time to maximum observed concentration (Tmax) of oxfendazole and its metabolites fenbendazole and fenbendazole sulfone
Time Frame: At different time points from pre-dose up to 48 hours after single dose administration
|
For single dose arms
|
At different time points from pre-dose up to 48 hours after single dose administration
|
Elimination half-life (t1/2) of oxfendazole and its metabolites fenbendazole and fenbendazole sulfone
Time Frame: At different time points from pre-dose up to 48 hours after single dose administration
|
For single dose arms
|
At different time points from pre-dose up to 48 hours after single dose administration
|
Area under the plasma concentration curve over dosing interval (AUCtau) of oxfendazole and its metabolites fenbendazole
Time Frame: At different time points from pre-dose up to 72 hours after last dose administration
|
For multiple doses arm
|
At different time points from pre-dose up to 72 hours after last dose administration
|
Accumulation Ratio (Racc) of oxfendazole and its metabolites fenbendazole
Time Frame: At different time points from pre-dose up to 72 hours after last dose administration
|
For multiple doses arm
|
At different time points from pre-dose up to 72 hours after last dose administration
|
Maximum observed concentration (Cmax) of oxfendazole and its metabolites fenbendazole and fenbendazole sulfone
Time Frame: At different time points from pre-dose up to 72 hours after last dose administration
|
For multiple doses arm
|
At different time points from pre-dose up to 72 hours after last dose administration
|
Time to maximum observed concentration (Tmax) of oxfendazole and its metabolites fenbendazole and fenbendazole sulfone
Time Frame: At different time points from pre-dose up to 72 hours after last dose administration
|
For multiple doses arm
|
At different time points from pre-dose up to 72 hours after last dose administration
|
Elimination half-life (t1/2) of oxfendazole and its metabolites fenbendazole and fenbendazole sulfone
Time Frame: At different time points from pre-dose up to 72 hours after last dose administration
|
For multiple doses arm
|
At different time points from pre-dose up to 72 hours after last dose administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of oxfendazole as measured by number of participants with treatment related adverse events and serious adverse events
Time Frame: From Day 1 to Day 14.
|
Number of participants with treatment related adverse events and serious adverse events
|
From Day 1 to Day 14.
|
Safety and tolerability of oxfendazole as measured by number of participants with physical examination findings
Time Frame: At different time points from baseline to Day 14
|
Number of participants with physical examination findings.
Standard examination done on skin, lymph nodes, head, eyes, ears, nose, throat, respiratory, cardiovascular, abdomen, extremities, musculoskeletal, and neurological.
|
At different time points from baseline to Day 14
|
Safety and tolerability of oxfendazole as measured by number of participants with vital signs findings
Time Frame: At different time points from baseline to Day 14
|
Number of participants with vital signs findings (heart rate, blood pressure, axillar temperature, respiratory rate,)
|
At different time points from baseline to Day 14
|
Safety and tolerability of oxfendazole as measured by number of participants with clinical laboratory test findings
Time Frame: At different time points from baseline to Day 14
|
Number of participants with relevant abnormal clinical laboratory tests results (hematology (hemoglobin, white blood cells (differentiation of eosinophils and neutrophils) and platelets), coagulation (prothrombin time and activated partial thromboplastin time), biochemistry (Creatinine, Alanine aminotransferase, Aspartate aminotransferase, total bilirubin, sodium, potassium, chloride, bicarbonate, blood urea nitrogen), urinalysis (proteinuria and glucose))
|
At different time points from baseline to Day 14
|
Safety and tolerability of oxfendazole as measured by number of participants with 12-lead ECG findings Safety and tolerability of oxfendazole as measured by the change in ECG parameters
Time Frame: Pre-dose, 1 and 2 hours after single dose administration on Day 1; Pre-dose, 1 and 2 hours after dose administration on Day 1 and pre-dose, 1 and 2 hours after dose administration on Day 5 (last dose) for multiple doses administration arm.
|
Number of participants with 12-lead ECG findings (heart rate (HR), PR interval, QRS, QT, QTcB, QTcF, cardiac rhythm and T wave morphology)
|
Pre-dose, 1 and 2 hours after single dose administration on Day 1; Pre-dose, 1 and 2 hours after dose administration on Day 1 and pre-dose, 1 and 2 hours after dose administration on Day 5 (last dose) for multiple doses administration arm.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Daniel Paris, Swiss TPH
- Principal Investigator: Said Jongo, Ifakara Health Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 21, 2022
Primary Completion (Actual)
November 7, 2022
Study Completion (Actual)
November 14, 2022
Study Registration Dates
First Submitted
May 28, 2021
First Submitted That Met QC Criteria
June 3, 2021
First Posted (Actual)
June 9, 2021
Study Record Updates
Last Update Posted (Actual)
December 20, 2022
Last Update Submitted That Met QC Criteria
December 19, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P1773-20A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
It is intended that Summary results will be shared once Clinical Study Report will be available.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Filariasis
-
University Hospitals Cleveland Medical CenterWashington University School of Medicine; Case Western Reserve University; Papua... and other collaboratorsRecruitingLymphatic Filariasis Elimination by Mass Drug Administration | Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis | Acceptability of Mass Drug Administration for Lymphatic FilariasisPapua New Guinea
-
National Institute of Allergy and Infectious Diseases...Completed
-
Washington University School of MedicineCase Western Reserve University; Regional Hospital of Agboville, Southern Cote...Active, not recruiting
-
University Hospitals Cleveland Medical CenterWashington University School of MedicineCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
The Task Force for Global HealthUnited States Agency for International Development (USAID)CompletedLymphedema | Lymphatic Filariasis | FilariasisIndia
-
The Task Force for Global HealthUnited States Agency for International Development (USAID)CompletedLymphedema | Lymphatic Filariasis | FilariasisSri Lanka
-
University Hospitals Cleveland Medical CenterPapua New Guinea Institute of Medical ResearchCompletedLymphatic FilariasisPapua New Guinea
-
University Hospitals Cleveland Medical CenterCompletedLymphatic FilariasisPapua New Guinea
-
Centre d'Appui à la lutte contre la MaladieWorld Health Organization; Malaria Research and Training Center, Bamako, MaliCompletedLymphatic Filariasis
Clinical Trials on Oxfendazole
-
Johns Hopkins Bloomberg School of Public HealthUniversidad Peruana Cayetano Heredia; School of Veterinary Medicine, Universidad...WithdrawnTenia Solium Infection
-
National Institute of Allergy and Infectious Diseases...CompletedHelminthic InfectionUnited States
-
Johns Hopkins Bloomberg School of Public HealthUniversidad Peruana Cayetano HerediaWithdrawn
-
National Institute of Allergy and Infectious Diseases...CompletedNeurocysticercosisUnited States
-
Universidad Peruana Cayetano HerediaNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruiting
-
Asociacion Benefica PrismaUniversity of Iowa; National Institutes of Health (NIH); University of Virginia; Policlinico Asociacion Benefica PRISMA-Laboratorio Satelite IQTLABNot yet recruiting
-
Oxfendazole Development GroupUniversidad Peruana Cayetano Heredia, Lima, PeruNot yet recruiting
-
University of ArkansasNational Institutes of Health (NIH); Ortho Biotech Clinical Affairs, L.L.C.Completed